PillRx only · Tablet · Oral
Raloxifene
Raloxifene Hydrochloride
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.239
Latest avg · Jul 22, 2026
-7%
Since Dec 17, 2025
3
Active US suppliers
80%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
2.3K
Rx · 2026 Q1
94K
Units dispensed
+8%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Cipla USA Inc. | unknown | 3 | SUPPLYING |
| Aphena Pharma Solutions - Tennessee, LLC | unknown | 1 | SUPPLYING |
| American Health Packaging | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Dec 4, 2019RECALLRecall (Class II): Raloxifene Hydrochloride Tablets, USP, 60 mg, 30 Tablets (3 x 10 blister cards), Rx Only, Packaged and Distributed by: …
Failed Dissolution Specifications: Low out of specification results obtained during stability testing. — Recalling firm: American Health Packaging — Nationwide within the United States